APHROFEMINE 100 MG 30 F.C. TABS

PHARMACOLOGY THE MECHANISM OF ACTION IN THE TREATMENT OF PREMENOPAUSAL WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER IS NOT KNOWN. FLIBANSERIN EXHIBITS AGONIST ACTIVITY AT 5-HT1A AND ANTAGONIST ACTIVITY AT 5-HT2A; MODERATE ANTAGONIST ACTIVITY IS SEEN AT THE 5-HT2B 5-HT2C AND DOPAMINE D4 RECEPTORS. INDICATIONS HYPOACTIVE SEXUAL DESIRE DISORDER: TREATMENT OF PREMENOPAUSAL WOMEN WITH ACQUIRED GENERALIZED HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) AS CHARACTERIZED BY LOW SEXUAL DESIRE THAT CAUSES MARKED DISTRESS OR INTERPERSONAL DIFFICULTY AND NOT DUE TO A COEXISTING MEDICAL OR PSYCHIATRIC CONDITION PROBLEMS WITHIN THE RELATIONSHIP OR THE EFFECTS OF A MEDICATION OR OTHER DRUG SUBSTANCE. LIMITATIONS OF USE: FLIBANSERIN IS NOT INDICATED FOR THE TREATMENT OF HSDD IN POSTMENOPAUSAL WOMEN OR IN MEN OR TO ENHANCE SEXUAL PERFORMANCE. DOSE: 100 MG ONCE DAILY AT BEDTIME. ASSESS TREATMENT EFFICACY AT 8 WEEKS AND DISCONTINUE IF SYMPTOMS HAVE NOT IMPROVED.